Alphatec (NASDAQ:ATEC) Shares Gap Down – Time to Sell?

Alphatec Holdings, Inc. (NASDAQ:ATEC) gapped down before the market opened on Wednesday . The stock had previously closed at $13.93, but opened at $13.26. Alphatec shares last traded at $13.6060, with a volume of 1,452,764 shares changing hands.

Alphatec News Roundup

Here are the key news stories impacting Alphatec this week:

• Positive Sentiment: Q4 revenue and growth: Alphatec reported revenue up ~20.4% year‑over‑year to about $212.9M, showing solid top‑line momentum and improved gross profit. This supports the company’s growth story. Zacks: ATEC Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Analyst support: Several firms reaffirmed Buy ratings (Needham, H.C. Wainwright) and set mid-$20s price targets, which may underpin buy‑side interest after the print. TipRanks: Needham reiterates Buy
• Neutral Sentiment: Profitability & cash flow trends: Management highlighted stronger profitability and a target of 17% revenue growth for 2026 while improving cash flow — positive longer‑term but depends on execution. Seeking Alpha: 17% growth target
• Neutral Sentiment: Mixed messaging on EPS: Different sources report different EPS figures (some outlets cite a small EPS beat on an adjusted basis; others report a GAAP diluted loss of about $0.14), creating investor confusion about the true earnings beat/miss. See call transcripts and presentation for detail. Seeking Alpha: Earnings call transcript
• Negative Sentiment: 2026 revenue guidance below some expectations: Several outlets flagged that the company’s 2026 revenue guide/assumptions were below street estimates, which appears to be the primary negative catalyst for the intraday sell‑off. Investing.com: Falls on guidance below estimates
• Negative Sentiment: Large insider/institutional selling highlighted by some data providers — plenty of reported insider sales in recent periods, which can weigh on sentiment even as institutions add positions. Quiver Quant: Stock falls on Q4 results and insider activity

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alphatec in a research note on Monday, December 29th. Piper Sandler restated an “overweight” rating on shares of Alphatec in a report on Wednesday. Loop Capital set a $25.00 target price on Alphatec in a research report on Wednesday, December 10th. Stifel Nicolaus initiated coverage on Alphatec in a report on Tuesday, October 28th. They set a “buy” rating and a $20.00 price target for the company. Finally, Canaccord Genuity Group raised their price objective on Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $22.82.

Alphatec Stock Down 2.8%

The stock has a 50-day moving average of $17.09 and a 200 day moving average of $17.15. The company has a market capitalization of $2.01 billion, a PE ratio of -13.02 and a beta of 1.01. The company has a quick ratio of 1.24, a current ratio of 1.99 and a debt-to-equity ratio of 43.02.

Alphatec (NASDAQ:ATEC) last announced its quarterly earnings data on Tuesday, February 24th. The medical technology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $212.93 million during the quarter, compared to the consensus estimate of $212.67 million. During the same quarter last year, the company earned ($0.23) EPS. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. Sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Insider Buying and Selling at Alphatec

In related news, CEO Patrick Miles sold 100,000 shares of Alphatec stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $21.01, for a total value of $2,101,000.00. Following the sale, the chief executive officer owned 5,135,398 shares of the company’s stock, valued at approximately $107,894,711.98. The trade was a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP David Sponsel sold 60,425 shares of the stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $13.79, for a total value of $833,260.75. Following the transaction, the executive vice president directly owned 349,500 shares of the company’s stock, valued at approximately $4,819,605. This trade represents a 14.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,436,125 shares of company stock valued at $29,385,878 in the last three months. 22.80% of the stock is owned by corporate insiders.

Institutional Trading of Alphatec

Hedge funds have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new position in shares of Alphatec during the 3rd quarter valued at $34,000. Osterweis Capital Management Inc. bought a new stake in Alphatec in the 2nd quarter valued at about $37,000. Northwestern Mutual Wealth Management Co. raised its stake in Alphatec by 157.1% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 1,571 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Alphatec by 22.4% during the second quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Alphatec during the third quarter worth about $73,000. 66.35% of the stock is currently owned by institutional investors.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.